Immutep

We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.

We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.

Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.

Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.

Immutep is listed on the Australian Stock Exchange (IMM) and on the NASDAQ Global Market (IMMP) in the U.S. (ADR's).  

Latest Media Releases

Immutep Announce Results of Annual General Meeting

01/11/2019 15:06:00

Results of Annual General Meeting The results of Immutep Limited (ACN 009 237 889) (ASX:IMM) Annual General Meeting held earlier today are set out in the attached document. All resolutions were …

Immutep - 2019 AGM CEO Presentation

01/11/2019 10:24:00

Immutep The Global leader in developing Lag-3 Therapeutics Annual General Meeting - November 2019 To view the presentation please download the attached PDF:

Latest News